$2.39
(2.54%)
Create an alert
Stocks and Shares ISAMirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Company Information
About this company
Key people
Michael G. Grey
Independent Chairman of the Board
Lon Cardon
Independent Director
William Carl Fairey
Independent Director
Laurent Fischer
Independent Director
Peter Radovich
President, Chief Operating Officer
Christopher Peetz
Chief Executive Officer, Co-Founder, Director
Eric H. Bjerkholt
Chief Financial Officer
Pamela Vig
Chief Scientific Officer, Head of Research
Lara Longpre
Chief Development Officer
Joanne Quan
Chief Medical Officer
Doug Sheehy
Chief Legal officer
Laura A. Brege
Independent Director
Click to see more
Key facts
- Shares in issue60.98m
- EPICMIRM
- ISINUS6047491013
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$5.73bn
- Employees369
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.